Cruise is now cruising some Houston streets. The self-driving car service has launched with $5 flat-rate rides. Photo courtesy of Cruise

For the first time, Houstonians can hail an autonomous vehicle to get from point A to point B, thanks to a tech company's latest market roll out.

San Francisco-based Cruise, which has launched in its hometown, Phoenix, and Austin over the past year and a half, previously announced Houston and Dallas as the company's next stops. Dallas, where Cruise is currently undergoing testing, will roll out its service by the end of the year.

As of today, October 12, Houstonians in the Downtown, Midtown, East Downtown, Montrose, Hyde Park, and River Oaks neighborhoods can hail a ride from an autonomous electric vehicle seven days a week between the hours of 9 pm to 6 am.

"We believe that everyone has a right to safer, more accessible and more affordable transportation, and we remain focused on cities first because that’s where our mission will have the greatest impact. Houston follows that city-first strategy with its densely traversed downtown, propensity for ridehail, and vibrant cultural center," Sola Lawal, Cruise's Houston manager, tells InnovationMap. "Cruise also shares in Houston’s Vision Zero mission to end traffic deaths and serious injuries by 2030 and we’re excited to address the transportation needs of Houston communities."

Although today marks the launch to the public, Cruise's employees and their friends and family have been testing out the service since August.

"People love this shift from working for your car as the driver, to the car working for you and the time this gives people back in their days," he explains. "A common reaction from first time riders starts with people being shocked and awed for the first two minutes then the ride becomes so normal that you forget you're in a driverless car."

Founded in 2013 by CEO, CTO, and President Kyle Vogt and Chief Product Officer Dan Kan, Cruise vehicles have self-driven over 5 million miles — 1 million of those miles were cruised on Texas streets. The company's fleet includes 400 electric vehicles powered by renewable energy.

Cruise's plan for Houston is to launch and grow from there, including launching larger passenger vehicles, the Origin fleet, for bigger groups of people.

"We always start small and methodically expand from there. For us it’s all about safety and how we expand in partnership with communities, so we let that be our guide for expansion vs arbitrary timelines," Lawal says. "Our goal is to continue to expand as quickly and safely as possible so we can get folks to the Rodeo when it starts and back home, anywhere in Houston, when it ends. You can expect expanded map areas, increased supply of AVs, and expanded hours until we are 24/7 across Houston."

Cruise has raised $10 billion in capital commitments from investors, including General Motors, Honda, Microsoft, T. Rowe Price, Walmart, and others. Additionally, the tech company has also a $5 billion credit line with GM Financial, giving it the financial support needed to scale. Strategically aligned with General Motors and Honda, Cruise has fully integrated manufacturing at scale.

Cruise, which touts a pricing model competitive to existing rideshares, is launching with $5 flat-rate rides for passengers.

"Houstonians who ride with us have the chance to be part of history in the making," Lawal tells Houston's to-be Cruise riders. "The industry has made incredible progress in the last two years but we are still in the early days of what’s to come as driverless ridehail becomes a reality for more people.

"We are proud of the service we’ve built so far and the safety record we have to show for it, but will always continue to improve. We're excited to launch with the community of Houston and we simply ask that you give it a try," he continues. "And when you do please give us feedback, we’d love to hear about your experience."

Origin, a larger, six-person self-driving vehicle, will also launch in the Houston market once Cruise rolls it out. Rendering courtesy of Cruise

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.